A role for CCN2 as a tumour marker was first reported by Vorwerk et al. who demonstrated by RT-PCR that it was specifically expressed in malignant lymphoblasts in childhood ALL (Vorwerk et al. 2000). The gene discussed is CCN2; the disease is acute lymphoblastic leukemia.